See more : Companhia Tecidos Santanense Ltda. (CTSA3.SA) Income Statement Analysis – Financial Results
Complete financial analysis of Cyclo Therapeutics, Inc. (CYTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cyclo Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Gokurakuyu Holdings Co., Ltd. (2340.T) Income Statement Analysis – Financial Results
- Ruijie Networks Co., Ltd. (301165.SZ) Income Statement Analysis – Financial Results
- AS ONE Corporation (7476.T) Income Statement Analysis – Financial Results
- Coeptis Therapeutics, Inc. (COEP) Income Statement Analysis – Financial Results
- Bakhu Holdings, Corp. (BKUH) Income Statement Analysis – Financial Results
Cyclo Therapeutics, Inc. (CYTH)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cyclotherapeutics.com
About Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.08M | 1.38M | 1.59M | 903.38K | 1.01M | 1.01M | 1.24M | 1.50M | 950.46K | 1.57M | 1.69M | 1.04M | 1.03M | 802.37K | 623.87K | 494.94K | 751.18K | 542.31K | 454.36K | 464.69K | 394.53K | 522.37K | 289.43K | 384.59K |
| Cost of Revenue | 98.46K | 138.93K | 156.08K | 66.40K | 75.49K | 105.03K | 132.92K | 198.43K | 124.43K | 272.64K | 426.02K | 139.68K | 273.76K | 114.66K | 110.83K | 99.32K | 118.40K | 125.19K | 66.66K | 78.83K | 45.43K | 84.48K | 34.03K | 99.22K |
| Gross Profit | 977.95K | 1.24M | 1.43M | 836.98K | 931.71K | 906.45K | 1.10M | 1.30M | 826.03K | 1.29M | 1.27M | 905.27K | 758.09K | 687.71K | 513.04K | 395.62K | 632.77K | 417.13K | 387.70K | 385.87K | 349.10K | 437.89K | 255.40K | 285.37K |
| Gross Profit Ratio | 90.85% | 89.90% | 90.16% | 92.65% | 92.50% | 89.62% | 89.26% | 86.80% | 86.91% | 82.61% | 74.84% | 86.63% | 73.47% | 85.71% | 82.24% | 79.93% | 84.24% | 76.92% | 85.33% | 83.04% | 88.48% | 83.83% | 88.24% | 74.20% |
| Research & Development | 14.18M | 9.00M | 9.15M | 6.10M | 4.87M | 2.71M | 2.29M | 1.86M | 658.51K | 94.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.66M | 7.81M | 6.50M | 3.68M | 3.43M | 2.43M | 2.62M | 2.64M | 2.22M | 1.53M | 639.54K | 560.17K | 799.60K | 678.64K | 693.33K | 520.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 3.90K | 13.06K | 18.34K | 5.01K | 5.89K | 5.64K | 7.85K | 7.16K | 7.57K | 10.90K | 8.91K | 10.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.83M | 7.82M | 6.52M | 3.68M | 3.44M | 2.44M | 2.63M | 2.65M | 2.23M | 1.55M | 648.45K | 570.98K | 799.60K | 678.64K | 693.33K | 520.06K | 439.10K | 350.68K | 500.32K | 664.78K | 263.50K | 240.54K | 279.11K | 548.79K |
| Other Expenses | 0.00 | 30.50K | 27.54K | 19.95K | 13.98K | 13.95K | 19.77K | 130.95K | 202.02K | 217.52K | 188.76K | 159.93K | 32.75K | 20.94K | 20.65K | 22.87K | 439.10K | 350.68K | 500.32K | 664.78K | 263.50K | 240.54K | 279.11K | 575.21K |
| Operating Expenses | 21.04M | 16.85M | 15.70M | 9.80M | 8.32M | 5.16M | 4.95M | 4.65M | 3.09M | 1.86M | 837.21K | 730.91K | 832.35K | 699.58K | 713.98K | 542.93K | 439.10K | 350.68K | 500.32K | 664.78K | 263.50K | 240.54K | 279.11K | 575.21K |
| Cost & Expenses | 21.13M | 16.99M | 15.85M | 9.86M | 8.40M | 5.27M | 5.08M | 4.85M | 3.22M | 2.13M | 1.26M | 870.59K | 1.11M | 814.24K | 824.81K | 642.25K | 557.51K | 475.86K | 566.97K | 743.61K | 308.93K | 325.02K | 313.14K | 674.43K |
| Interest Income | 0.00 | 12.47K | 3.41K | 19.80K | 12.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.60K | 31.29K | 33.67K | 53.87K | 61.80K | 25.81K | 4.31K | 0.00 | 1.82K | 10.75K | 11.05K | 13.96K | 12.03K | 22.60K | 30.92K | 35.44K | 28.29K | |
| Depreciation & Amortization | 19.28K | 19.48K | 16.83K | 12.76K | 5.68K | 10.12K | 9.27K | 107.10K | 169.03K | 152.45K | 148.04K | 142.64K | 32.75K | 20.94K | 20.58K | 22.87K | 24.37K | 27.46K | 35.01K | 27.76K | 37.82K | 24.19K | 51.29K | 26.41K |
| EBITDA | -20.03M | -15.60M | -14.27M | -8.95M | -7.39M | -4.24M | -3.82M | -4.09M | -2.23M | -406.57K | 486.82K | 303.65K | -39.21K | 12.72K | -172.55K | -188.55K | 218.04K | -63.32K | -77.60K | -251.15K | 90.92K | 221.54K | 27.58K | -66.02K |
| EBITDA Ratio | -1,860.90% | -1,145.03% | -897.54% | -992.49% | -719.16% | -419.60% | -309.54% | -215.26% | -220.57% | -26.15% | 34.14% | 30.34% | -4.02% | 1.13% | -28.91% | -25.14% | 26.28% | 46.31% | -56.50% | 4.17% | 29.51% | 42.57% | 8.63% | -69.09% |
| Operating Income | -20.05M | -15.61M | -14.27M | -8.96M | -7.39M | -4.27M | -3.84M | -4.21M | -2.41M | -562.31K | 336.65K | 157.49K | -74.26K | -11.87K | -200.94K | -239.47K | 193.67K | -45.90K | -112.61K | -278.91K | 85.60K | 197.35K | -23.71K | -289.84K |
| Operating Income Ratio | -1,862.69% | -1,134.76% | -899.77% | -991.85% | -733.80% | -421.84% | -310.51% | -279.85% | -253.22% | -35.87% | 19.88% | 15.07% | -7.20% | -1.48% | -32.21% | -48.38% | 25.78% | -8.46% | -24.78% | -60.02% | 21.70% | 37.78% | -8.19% | -75.36% |
| Total Other Income/Expenses | -7.25K | 171.00K | 3.41K | 19.80K | 12.03K | 11.77K | 10.26K | -17.95K | -24.62K | -30.37K | -51.74K | -58.29K | -23.51K | -662.00 | 7.81K | 26.24K | 9.89K | -168.28K | 165.15K | -282.58K | -15.63K | -31.77K | -32.83K | 171.41K |
| Income Before Tax | -20.06M | -15.45M | -14.29M | -8.94M | -7.53M | -4.26M | -3.83M | -4.22M | -2.43M | -592.69K | 284.91K | 99.20K | -97.77K | -12.53K | -193.13K | -213.23K | 203.55K | -101.83K | 52.54K | -561.49K | 69.98K | 165.58K | -56.54K | -315.83K |
| Income Before Tax Ratio | -1,863.36% | -1,123.08% | -900.94% | -989.80% | -747.87% | -420.68% | -309.68% | -281.04% | -255.81% | -37.81% | 16.83% | 9.49% | -9.47% | -1.56% | -30.96% | -43.08% | 27.10% | -18.78% | 11.56% | -120.83% | 17.74% | 31.70% | -19.54% | -82.12% |
| Income Tax Expense | 0.00 | -171.00K | 18.52K | -18.53K | 141.75K | 11.77K | 0.00 | 28.60K | 120.00K | 33.67K | 80.00K | 25.00K | 25.81K | 25.00K | 0.00 | 200.00K | -450.00K | 168.28K | 225.00K | 282.58K | -225.00K | 31.77K | 90.17K | 195.00K |
| Net Income | -20.06M | -15.28M | -14.31M | -8.92M | -7.67M | -4.26M | -3.83M | -4.22M | -2.55M | -592.69K | 204.91K | 74.20K | -97.77K | -37.53K | -193.13K | -413.23K | 653.55K | -101.83K | -172.46K | -561.49K | 294.98K | 165.58K | -113.88K | -510.83K |
| Net Income Ratio | -1,863.36% | -1,110.65% | -902.10% | -987.75% | -761.94% | -420.68% | -309.68% | -281.04% | -268.44% | -37.81% | 12.10% | 7.10% | -9.47% | -4.68% | -30.96% | -83.49% | 87.00% | -18.78% | -37.96% | -120.83% | 74.77% | 31.70% | -39.35% | -132.82% |
| EPS | -1.23 | -1.81 | -2.25 | -5.58 | -7.09 | -5.20 | -5.32 | -6.67 | -4.54 | -1.17 | 1.00 | 1.00 | -0.27 | -0.11 | -0.67 | -1.76 | 3.60 | -0.69 | -1.44 | -7.76 | 5.00 | 3.00 | -2.59 | -13.80 |
| EPS Diluted | -1.23 | -1.81 | -2.25 | -5.58 | -7.09 | -5.20 | -5.32 | -6.67 | -4.54 | -1.17 | 1.00 | 1.00 | -0.27 | -0.11 | -0.67 | -1.76 | 3.60 | -0.69 | -1.44 | -7.76 | 5.00 | 3.00 | -2.59 | -13.80 |
| Weighted Avg Shares Out | 16.33M | 8.44M | 6.37M | 1.60M | 1.08M | 817.57K | 720.37K | 633.54K | 562.09K | 505.43K | 371.66K | 366.80K | 358.07K | 337.11K | 287.51K | 235.33K | 179.20K | 148.15K | 120.18K | 72.32K | 50.05K | 47.91K | 43.89K | 37.02K |
| Weighted Avg Shares Out (Dil) | 16.33M | 8.44M | 6.37M | 1.60M | 1.08M | 817.57K | 720.37K | 633.54K | 562.09K | 505.43K | 371.66K | 366.80K | 358.07K | 337.11K | 287.51K | 235.33K | 179.20K | 148.15K | 120.18K | 72.32K | 50.05K | 47.91K | 43.89K | 37.02K |
Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Lise Kjems, MD, PhD,...
Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Professor Caroline Hastings, MD...
Cyclo Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief...
Cyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the poster presentation of its...
Cyclo Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief...
Anti-Amyloid Drugs: The Failure Of Success
Anti-Amyloid Drugs: The Failure Of Success
Cyclo Therapeutics (CYTH) Stock: Why The Price Dropped Today
The stock price of Cyclo Therapeutics Inc (NASDAQ: CYTH) fell by over 15% pre-market today. This is why it happened.
Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease
Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease
Cyclo Therapeutics to Present at the Virtual Investor Roundtable Event
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief...
Cyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Support for Research to Find a Treatment
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today joins with the global Niemann-Pick Disease community in recognizing Niemann-Pick Disease...
Source: https://incomestatements.info
Category: Stock Reports